Modern Active Surveillance in Prostate Cancer: A Narrative Review
Details
Publication Year 2023-02,Volume 21,Issue #1,Page 115-123
Journal Title
Clinical Genitourinary Cancer
Publication Type
Review
Abstract
The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection criteria and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection criteria recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection.
Publisher
Elsevier
Keywords
Male; Humans; *Watchful Waiting; *Prostatic Neoplasms/diagnosis/therapy/epidemiology; Morbidity; Patient Selection; Prostate-Specific Antigen; Active surveillance; Intermediate risk prostate cancer; Low risk prostate cancer; Mri; Risk stratification
Department(s)
Surgical Oncology
PubMed ID
36443163
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-13 07:55:11
Last Modified: 2023-06-13 07:56:08

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙